Cabaletta Bio   Report issue

For profit Phase 1 Phase 2
Founded: Philadelphia PA United States (2017)

Organization Overview

First Clinical Trial
2020
NCT04422912
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Cabaletta Bio

Active Ingredients

Drugs in Phase 2 Trials (4)

cab-201 (1 trial)

caba-201 (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fludarabine (fludara) (1 trial)

Drugs in Phase 1 Trials (2)

dsg3-caart (1 trial)

musk-caart (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Pemphigus (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 6